Table of Content

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global & Asia Pacific Biologics Contract Manufacturing Market

4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global & Asia Pacific Biologics Contract Manufacturing Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights
5.1. Biologics Contract Manufacturing: Overview
5.2. Trends in Biopharma Contract Manufacturing
5.3. Key Industry Events (mergers, acquisitions, collaborations, approvals, etc.)
5.4. COVID-19 Pandemic Impact on Industry

6. Global & Asia Pacific Biologics Contract Manufacturing Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type, 2017–2031
6.3.1. Monoclonal Antibodies
6.3.2. Recombinant Proteins
6.3.3. Vaccines
6.3.4. Molecular Therapy
6.3.5. Others
6.4. Market Attractiveness Analysis, by Type

7. Asia Pacific Biologics Contract Manufacturing Market Analysis and Forecast, by Country/Sub-Region
7.1. Key Findings
7.2. Market Value Forecast, by Country/Sub-Region
7.2.1. Japan
7.2.2. South Korea
7.2.3. Taiwan
7.2.4. Singapore
7.2.5. Thailand
7.2.6. India
7.2.7. Rest of Asia Pacific
7.3. Market Attractiveness Analysis, by Country/Sub-Region

8. Japan Biologics Contract Manufacturing Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.2. Market Value Forecast, by Type, 2017–2031
8.2.1. Monoclonal Antibodies
8.2.2. Recombinant Proteins
8.2.3. Vaccines
8.2.4. Molecular Therapy
8.2.5. Others
8.3. Market Attractiveness Analysis
8.3.1. By Type

9. South Korea Biologics Contract Manufacturing Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Type, 2017–2031
9.2.1. Monoclonal Antibodies
9.2.2. Recombinant Proteins
9.2.3. Vaccines
9.2.4. Molecular Therapy
9.2.5. Others
9.3. Market Attractiveness Analysis
9.3.1. By Type

10. Taiwan Biologics Contract Manufacturing Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2017–2031
10.2.1. Monoclonal Antibodies
10.2.2. Recombinant Proteins
10.2.3. Vaccines
10.2.4. Molecular Therapy
10.2.5. Others
10.3. Market Attractiveness Analysis
10.3.1. By Type

11. Singapore Biologics Contract Manufacturing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017–2031
11.2.1. Monoclonal Antibodies
11.2.2. Recombinant Proteins
11.2.3. Vaccines
11.2.4. Molecular Therapy
11.2.5. Others
11.3. Market Attractiveness Analysis
11.3.1. By Type

12. Thailand Biologics Contract Manufacturing Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017–2031
12.2.1. Monoclonal Antibodies
12.2.2. Recombinant Proteins
12.2.3. Vaccines
12.2.4. Molecular Therapy
12.2.5. Others
12.3. Market Attractiveness Analysis
12.3.1. By Type

13. India Biologics Contract Manufacturing Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017–2031
13.2.1. Monoclonal Antibodies
13.2.2. Recombinant Proteins
13.2.3. Vaccines
13.2.4. Molecular Therapy
13.2.5. Others
13.3. Market Attractiveness Analysis
13.3.1. By Type

14. Rest of Asia Pacific Biologics Contract Manufacturing Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017–2031
14.2.1. Monoclonal Antibodies
14.2.2. Recombinant Proteins
14.2.3. Vaccines
14.2.4. Molecular Therapy
14.2.5. Others
14.3. Market Attractiveness Analysis
14.3.1. By Type

15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2020
15.3. Company Profiles
15.3.1. Lonza Group
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Strategic Overview
15.3.1.4. SWOT Analysis
15.3.2. Samsung Biologics Co., Ltd.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Strategic Overview
15.3.2.4. SWOT Analysis
15.3.3. Patheon by Thermo Fisher Scientific, Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Strategic Overview
15.3.3.4. SWOT Analysis
15.3.4. Siegfried Holding AG
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Strategic Overview
15.3.4.4. SWOT Analysis
15.3.5. Cambrex Corporation
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Strategic Overview
15.3.5.4. SWOT Analysis
15.3.6. Boehringer Ingelheim
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Strategic Overview
15.3.6.4. SWOT Analysis
15.3.7. Recipharm Pharmaceuticals
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Strategic Overview
15.3.7.4. SWOT Analysis
15.3.8. Catalent Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Strategic Overview
15.3.8.4. SWOT Analysis
15.3.9. WuXi Biologics
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Strategic Overview
15.3.9.4. SWOT Analysis
15.3.10. Fujifilm Holding Corporation
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Strategic Overview
15.3.10.4. SWOT Analysis
15.3.11. AbbVie, Inc.
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Strategic Overview
15.3.11.4. SWOT Analysis



List of Figures

List of Figures

Figure 01: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Asia Pacific Biologics Contract Manufacturing Market Value Share, by Type, 2020

Figure 03: Asia Pacific Biologics Contract Manufacturing Market Value Share, by Country/Sub-Regions, 2020

Figure 04: Asia Pacific Biologics Contract Manufacturing Market Value Share Analysis, by Type, 2020 and 2031

Figure 05: Asia Pacific Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 06: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn), by Monoclonal Antibodies, 2017?2031

Figure 07: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn), by Recombinant Proteins, 2017?2031

Figure 08: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn), by Vaccines, 2017?2031

Figure 09: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn), by Molecular Therapy, 2017?2031

Figure 10: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn), by Others, 2017–2031

Figure 11: Asia Pacific Biologics Contract Manufacturing Market Attractiveness Analysis, by Region, 2021–2031

Figure 12: Asia Pacific Biologics Contract Manufacturing Market Value Share Analysis, by Region, 2020 and 2031

Figure 13: Japan Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 14: Japan Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 15: Japan Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 16: South Korea Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 17: South Korea Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 18: South Korea Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 19: Taiwan Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 20: Taiwan Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 21: Taiwan Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 22: Singapore Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 23: Singapore Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 24: Singapore Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 25: Thailand Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 26: Thailand Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 27: Thailand Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 28: India Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 29: India Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 30: India Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

Figure 31: Rest of Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 32: Rest of Asia Pacific Biologics Contract Manufacturing Market Value Share (%), by Type, 2020 and 2031

Figure 33: Rest of Asia Pacific Biologics Contract Manufacturing Market Attractiveness Analysis, by Type, 2021–2031

List of Tables

List of Tables

Table 01: Global Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017?2031

Table 02: Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

Table 03: Japan Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 04: South Korea Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 05: Taiwan Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 06: Singapore Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 07: Thailand Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 08: India Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 09: Rest of Asia Pacific Biologics Contract Manufacturing Market Value (US$ Mn) Forecast, by Type, 2017–2031